Provided By GlobeNewswire
Last update: Apr 1, 2025
SALT LAKE CITY, April 01, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Jones Healthcare and Technology Innovation Conference and host 1x1 investor meetings.
Read more at globenewswire.comNASDAQ:CLNN (10/15/2025, 8:21:23 PM)
8.89
+0.3 (+3.49%)
Find more stocks in the Stock Screener